[go: up one dir, main page]

WO2006008008A3 - Agents diagnostiques et therapeutiques pour pathologies associees au facteur nucleaire d'hepatocyte 4, alpha (hnf4a) - Google Patents

Agents diagnostiques et therapeutiques pour pathologies associees au facteur nucleaire d'hepatocyte 4, alpha (hnf4a) Download PDF

Info

Publication number
WO2006008008A3
WO2006008008A3 PCT/EP2005/007457 EP2005007457W WO2006008008A3 WO 2006008008 A3 WO2006008008 A3 WO 2006008008A3 EP 2005007457 W EP2005007457 W EP 2005007457W WO 2006008008 A3 WO2006008008 A3 WO 2006008008A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
hnf4a
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2005/007457
Other languages
English (en)
Other versions
WO2006008008A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts, Holger Summer filed Critical Bayer Healthcare Ag
Publication of WO2006008008A2 publication Critical patent/WO2006008008A2/fr
Publication of WO2006008008A3 publication Critical patent/WO2006008008A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un HNF4A humain qui est associé à des pathologies gastro-intestinales et hépatiques, des troubles cancéreux, des troubles cardio-vasculaires, des troubles métaboliques, des troubles inflammatoires, des troubles musculaires et osseux, des troubles respiratoires, des troubles de la reproduction et des troubles urologiques. L'invention a également pour objet des essais pour identifier des composés utiles pour le traitement ou la prévention de pathologies gastro-intestinales et hépatiques, de troubles cancéreux, de troubles cardio-vasculaires, de troubles métaboliques, de troubles inflammatoires, de troubles musculaires et osseux, de troubles respiratoires, de troubles de la reproduction et de troubles urologiques. L'invention concerne aussi des composés qui se lient à HNF4A et/ou activent ou inhibent son activité, ainsi que des compositions pharmaceutiques qui comprennent de tels composés.
PCT/EP2005/007457 2004-07-23 2005-07-09 Agents diagnostiques et therapeutiques pour pathologies associees au facteur nucleaire d'hepatocyte 4, alpha (hnf4a) WO2006008008A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04017447 2004-07-23
EP04017447.6 2004-07-23

Publications (2)

Publication Number Publication Date
WO2006008008A2 WO2006008008A2 (fr) 2006-01-26
WO2006008008A3 true WO2006008008A3 (fr) 2006-06-22

Family

ID=35618139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/007457 WO2006008008A2 (fr) 2004-07-23 2005-07-09 Agents diagnostiques et therapeutiques pour pathologies associees au facteur nucleaire d'hepatocyte 4, alpha (hnf4a)

Country Status (1)

Country Link
WO (1) WO2006008008A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9981048B2 (en) 2013-02-12 2018-05-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods for the treatment and prevention of liver disease
CN119563108A (zh) * 2022-05-01 2025-03-04 耶达研究发展公司 用于减轻癌症相关恶病质的hnf4a的重表达

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023780A1 (fr) * 1996-11-26 1998-06-04 Joslin Diabetes Center, Inc. Procedes de diagnostic et de traitement du diabete
US6025196A (en) * 1990-12-21 2000-02-15 The Rockefeller University Chimeric proteins comprising liver enriched transcription factors and nucleic acids encoding the same
WO2002024227A1 (fr) * 2000-09-20 2002-03-28 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de proliferation de cellules tumorales
WO2002072874A1 (fr) * 2001-03-14 2002-09-19 Fujisawa Pharmaceutical Co., Ltd. Procede de criblage d'un agoniste hnf4$g(a)
WO2003016559A2 (fr) * 2001-08-17 2003-02-27 Novo Nordisk A/S Procede de traitement du diabete
WO2003064628A2 (fr) * 2002-02-01 2003-08-07 Curagen Corporation Mandrin a vide faisant intervenir un materiau fritte et procede de fabrication
WO2004023973A2 (fr) * 2002-09-12 2004-03-25 Incyte Corporation Molecules utilisees a des fins diagnostiques et therapeutiques

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025196A (en) * 1990-12-21 2000-02-15 The Rockefeller University Chimeric proteins comprising liver enriched transcription factors and nucleic acids encoding the same
WO1998023780A1 (fr) * 1996-11-26 1998-06-04 Joslin Diabetes Center, Inc. Procedes de diagnostic et de traitement du diabete
WO2002024227A1 (fr) * 2000-09-20 2002-03-28 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de proliferation de cellules tumorales
WO2002072874A1 (fr) * 2001-03-14 2002-09-19 Fujisawa Pharmaceutical Co., Ltd. Procede de criblage d'un agoniste hnf4$g(a)
WO2003016559A2 (fr) * 2001-08-17 2003-02-27 Novo Nordisk A/S Procede de traitement du diabete
WO2003064628A2 (fr) * 2002-02-01 2003-08-07 Curagen Corporation Mandrin a vide faisant intervenir un materiau fritte et procede de fabrication
WO2004023973A2 (fr) * 2002-09-12 2004-03-25 Incyte Corporation Molecules utilisees a des fins diagnostiques et therapeutiques

Also Published As

Publication number Publication date
WO2006008008A2 (fr) 2006-01-26

Similar Documents

Publication Publication Date Title
WO2004104216A3 (fr) Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4)
WO2005075665A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees a la kallikreine plasmatique (klkb1)
WO2005106492A3 (fr) Diagnostic et traitement therapeutique des maladies associees au recepteur 3 de la chimiokine c-c (ccr3)
WO2006008002A3 (fr) Agents diagnostiques et therapeutiques pour pathologies associees a la kallikreine 1 (klk1)
WO2005106012A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
WO2005050225A3 (fr) Outils de diagnostic et de traitement de maladies associees au recepteur 84 couple aux proteines g (gpr84)
WO2006008008A3 (fr) Agents diagnostiques et therapeutiques pour pathologies associees au facteur nucleaire d'hepatocyte 4, alpha (hnf4a)
WO2005095973A3 (fr) Methodes diagnostiques et therapeutiques pour des maladies associees au recepteur 54 couple a la proteine g (gpr54)
WO2005106471A3 (fr) Diagnostics et therapies pour des maladies associees a un recepteur 4 de chimiokine c-c (ccr4)
WO2005103702A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur 2 de la chimiokine cxc (cxcr2)
WO2005118840A3 (fr) Elements diagnostiques therapeutiques pour des maladies associees a la kallikreine 10 (klk10)
WO2005078117A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la kallikreine 6 (klk6)
WO2004082568A3 (fr) Diagnostics et traitements contre des maladies associees au recepteur 5a du composant du complement (c5ar)
WO2005040825A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 20 couple a la proteine g (gpr20)
WO2005040211A3 (fr) Composes destines au diagnostic et au traitement de maladies associees au recepteur 1 couple aux proteines g (gpr1)
WO2004104574A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur de chimiokine c-c de type 7 (ccr7)
WO2005075662A3 (fr) Methodes diagnostiques et therapeutiques des maladies associees au kallikrein 2 (klk2)
WO2005103711A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees au recepteur 1 des chimiokines cxc (cxcr1)
WO2005059546A3 (fr) Diagnostics et therapeutique destines au traitement de maladies associees au recepteur couple aux proteines g 35 (gpr35)
WO2005095984A3 (fr) Compositions diagnostiques et therapeutiques pour des maladies associees au recepteur adrenergique alpha 2a couple a la proteine g (adra2a)
WO2005103690A3 (fr) Diagnostic et therapeutique de maladies associees au recepteur de l'hormone de liberation de la corticotropine 2 (crhr2)
WO2005040822A3 (fr) Diagnostics et therapeutiques pour des maladies associees au recepteur 25 couple a la proteine g (gpr25)
WO2004106934A3 (fr) Diagnostics et agents therapeutiques destines a des maladies liees au recepteur 7 de 5-hydroxytryptamine (serotonine) (5-ht7)
WO2004104595A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a la x-pro dipeptidase (pepd)
WO2005083105A3 (fr) Diagnostic et traitement de maladies associees a la glycogene synthase kinase 3 beta (gsk3b)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase